First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

Ferrero, James, Williams, Leslie, Stella, Heather, Leitermann, Kate, Mikulskis, Alvydas, O'Gorman, John, Sevigny, Jeff·2016·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1016/j.trci.2016.06.002

Cited by (188)

Items 101–188 of 188

  1. Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease
    Ying Hao, Mingrui Dong, Yingtong Sun, Xiaohui Duan, Wenquan Niu · 2023 · Frontiers in Neurology
  2. Profiling aducanumab as a treatment option for Alzheimer’s disease: an overview of efficacy, safety and tolerability
    Shreeya Thussu, Aniketh Naidu, Sindhu Manivannan, George Thomas Grossberg · 2024 · Expert Review of Neurotherapeutics
  3. The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers
    Victòria Valls-Comamala, Biuse Guivernau, Jaume Bonet, Marta Puig, Alex Perálvarez‐Marín, Ernest Palomer, Xavier Fernàndez‐Busquets, Xavier Altafaj, Marta Tajes, Albert Puig‐Pijoan et al. · 2017 · Oncotarget
  4. Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
    Sudha Raghunath, Yifat Glikmann‐Johnston, John G. Hanly, Eric Francis Morand, Julie C. Stout, Alberta Yik-Bun Hoi · 2022 · The Lancet Rheumatology
  5. Identification of Potential Repurposable Drugs in Alzheimer’s Disease Exploiting a Bioinformatics Analysis
    Giulia Fiscon, Pasquale Sibilio, Alessio Funari, Federica Conte, Paola Paci · 2022 · Journal of Personalized Medicine
  6. Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies
    Avtar Singh Gautam, Shivam Kumar Pandey, Vaibhav Lasure, Sachin Dubey, Rakesh Kumar Singh · 2023 · Expert Opinion on Biological Therapy
  7. Phytochemical Nanoparticles for the Treatment of Neurological Disorders
    Touraj Ehtezazi, Satyajit Dey Sarker · 2025 · Phytochemical Analysis
  8. The endocrine pancreas of old obesehyperglycemic mice.
    Sighild Westman · 1968 · PubMed
  9. The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer’s Disease
    Maria Podsiedlik, Magdalena Markowicz-Piasecka, Joanna Sikora · 2022 · International Journal of Molecular Sciences
  10. Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders
    Noha N. Lasheen, Salma Allam, Abdullrahman Elgarawany, Darin W Aswa, Rana Mansour, Ziad ElDosoky Farouk · 2024 · The Journal of Physiological Sciences
  11. Amyloid-Directed Antibodies: Past, Present, and Future
    Keith Noorda, Kevin J. Noorda, Marwan N. Sabbagh, John A. Bertelson, Jonathan Singer, Boris Decourt · 2024 · Journal of Alzheimer s Disease
  12. α-synuclein monoclonal antibodies in Parkinson's disease: A failed promise or unmet potential?
    Mark Messak, Ahmed Abdelmageed, Youssef A. Khattab, Gergis Altalab, Youssef Mandour, Omar Shaker · 2026 · Journal of the Neurological Sciences
  13. Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis
    Artur Menegaz de Almeida, Marianna Gerardo Hidalgo Santos Jorge Leite, Lucca Moreira Lopes, Pedro Lucas Gomes Lima, Maria Luísa Siegloch Barros, Samuel Luca Rocha Pinheiro, Ítalo Barros Andrade, Patrícia Viana, Victória Morbach, Gabriel Marinheiro et al. · 2024 · Expert Review of Neurotherapeutics
  14. Characterization of the molecular interactions between resveratrol derivatives and death‐associated protein kinase 1
    Takeshi Yokoyama, Katsuhiro Kusaka · 2023 · FEBS Journal
  15. In vitro Blood–Brain barrier model based on recombinant spider silk protein nanomembranes for evaluation of transcytosis capability of biomolecules
    Linnea Charlotta Hjelm, My Hedhammar, John Löfblom · 2023 · Biochemical and Biophysical Research Communications
  16. Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer’s Disease
    Martine B. Grenon, Maria-Tzousi Papavergi, Praveen Bathini, Martin J. Sadowski, Cynthia Ann Lemere · 2024 · International Journal of Molecular Sciences
  17. The involvement of reactive oxygen species in causing chronic cardiovascular and neurodegenerative diseases and some cancers
    Jasneet Tiwana, Anureet K. Shah, Naranjan S. Dhalla · 2024 · Scripta Medica
  18. Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease
    Shubhima Grover, Seema Jain · 2022 · Drugs & Therapy Perspectives
  19. Aducanumab: una mirada dos años después de su aprobación
    Astrid Torres Jaimes, Loida Camargo, Norman López · 2024 · Biomédica
  20. FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?
    Martin J. Higgins, Veronica Wasef, Andrea Kwakowsky · 2026 · International Journal of Molecular Sciences
  21. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies
    Yaru Yang, Hongyan Qiu, Yuru Fan, Qin Zhang, Huiling Qin, Juan Wu, Xuan Zhang, Yueyue Liu, Renpeng Zhou, Qian Zhang et al. · 2024 · Alzheimer s Research & Therapy
  22. Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: Interference by cholinesterase inhibitors
    Karima Schwab, Dilyara Lauer, Mandy Magbagbeolu, Franz Theuring, Anna Gąsiorowska, Maciej Zadrożny, Charles R. Harrington, Claude M. Wischik, Grażyna Niewiadomska, Gernot Riedel · 2024 · Brain Research Bulletin
  23. Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy
    Yona Levites, Cory C. Funk, Xue Wang, Paramita Chakrabarty, Karen N. McFarland, Baxter Bramblett, Veronica O’Neal, Xufei Liu, Thomas B. Ladd, Max Robinson et al. · 2021 · Molecular Neurodegeneration
  24. Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia
    Karima Schwab, Lianne Robinson, Anne Annschuetz, Eline Dreesen, Mandy Magbagbeolu, Valeria Melis, Franz Theuring, Charles R. Harrington, Claude M. Wischik, Gernot Riedel · 2024 · Brain Research Bulletin
  25. Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report
    Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Natelson love, Aparna Singhal · 2022 · Radiology Case Reports
  26. Super-Resolution Deep Learning Reconstruction for T2*-Weighted Images: Improvement in Microbleed Lesion Detection and Image Quality
    Yusuke Asari, Koichiro Yasaka, Kazuki Endo, Jun Kanzawa, Naomasa Okimoto, Yusuke Watanabe, Yuichi Suzuki, Shiori Amemiya, Shigeru Kiryu, Osamu Abe · 2025 · Journal of Imaging Informatics in Medicine
  27. Current clinical approaches in neurodegenerative diseases
    Miguel Fernandes Gago, Álvaro Sosa Machado, Sofia Rocha · 2020 · Elsevier eBooks
  28. Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease
    Shawn J. Kile, William J. Au, Carol A. Parise, Kimberley Rose, Tammy Donnel, Andrea I. Hankins, Yvonne Au, Matthew Chan, Azad Ghassemi · 2021 · BMC Neuroscience
  29. Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer’s disease in adults without dementia: a systematic review and meta-analysis protocol
    Takashi Nihashi, Keita Sakurai, Takashi Kato, Yasuyuki Kimura, Kengo Ito, Akinori Nakamura, Teruhiko Terasawa · 2024 · Diagnostic and Prognostic Research
  30. Aducanumab for Alzheimer's disease: An update
    Thaarvena Retinasamy, Mohd. Farooq Shaikh · 2021 · Neuroscience Research Notes
  31. Natural Autoantibodies in Health and Disease
    Peggy Lymberi, Μαρκέλλα Ζαννίκου, Aikaterini Hatzioannou · 2021 · Elsevier eBooks
  32. Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
    Yuu Ohno, Riley Murphy, Matthew K. Choi, Weijun Ou, Rachita K. Sumbria · 2022 · Journal of Visualized Experiments
  33. Comparative examination of the pons and corpus callosum as reference regions for quantitative evaluation in positron emission tomography imaging for Alzheimer’s disease using 11C-Pittsburgh Compound-B
    Tomohiro Tada, Kazuhiro Hara, Naotoshi Fujita, Yoshinori Ito, Hiroshi Yamaguchi, Reiko Ohdake, Kazuya Kawabata, Aya Ogura, Toshiyasu Kato, Takamasa Yokoi et al. · 2023 · Annals of Nuclear Medicine
  34. Large-scale seroepidemiology uncovers nephro-urological pathologies in persons with tau autoimmunity
    Andreia D. Magalhães, Marc Emmenegger, Elena De Cecco, Manfredi C. Carta, Karl Frontzek, Andra Chincisan, Jingjing Guo, Simone Hornemann, Adriano Aguzzi · 2021 · medRxiv
  35. Covalent fragment inhibits intramembrane proteolysis
    Eden, Angela, Zhao, Jing, Xiao, Yuanyuan, Gibson, James, Wang, Chunyu · 2022 · Frontiers in Molecular Biosciences
  36. Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer’s disease
    Lindsay A. Welikovitch, Derek H. Oakley, Rachel E. Bennett, Alberto Serrano‐Pozo, Haoyang Zhu, Nancy E. Ruiz‐Uribe, Theodore J. Zwang, Lori Beth Chibnik, Teresa Gómez‐Isla, Matthew P. Frosch et al. · 2026 · Acta Neuropathologica
  37. Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
    Noha Aljehani, Seba Talat Al‐Gunaid, Alhassan H Hobani, Mohammad F Alhinti, Yahya Khubrani, Lama M Abu-Hamoud, Aljawharah Abdulrahman Alrayes, Lama B Alharbi, Ali A Sultan, Doaa A. Turkistani et al. · 2024 · Cureus
  38. Kausale Therapie der Alzheimer-Krankheit: Amyloidantikörper
    Matthias Pawlowski, Tobias Warnecke · 2022 · Die Innere Medizin
  39. Hope or hype? Aducanumab as a magic bullet for Alzheimer’s disease
    Wei‐Jye Lin, Chuan Xiao, Stephen R. Salton · 2022 · BIO Integration
  40. A novel GSK3β inhibitor ameliorates tau aggregation and neuroinflammation in Alzheimer's disease
    Xinyue Ning, Wenjie Liu, Lijun Zhou, Nan Wang, Xinzhu Li, Limeng Wu, Zhenshu Li, Ai-Zhu Yang, Siyuan Liu, Zonghe Xu et al. · 2025 · Neurochemistry International
  41. Large-scale seroepidemiology uncovers nephro-urological pathologies in people with tau autoimmunity
    Magalhães, Andreia D., Emmenegger, Marc, De Cecco, Elena, Carta, Manfredi, Frontzek, Karl, Chincisan, Andra, Guo, Jingjing, Hornemann, Simone, Aguzzi, Adriano · 2025 · PLOS Biology
  42. Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) Modeling
    Salih Benamara, Erik Sjögren, Florence Gattacceca, Marylore Chenel, Antoine Deslandes, Laurent Nguyen, Donato Teutonico · 2025 · ACS Pharmacology & Translational Science
  43. Near‐Infrared Aggregation‐Induced Emission Luminogens for In Vivo Theranostics of Alzheimer's Disease
    Tianfu Zhang, Xiaoyu Chen, Congmin Yuan, Xiaobin Pang, Ping Shangguan, Yi‐Sheng Liu, Lulu Han, Jianwei Sun, Jacky W. Y. Lam, Yang Liu et al. · 2022 · Angewandte Chemie
  44. TO MARKET, TO MARKET–2021: MACROMOLECULAR THERAPEUTICS
    Nicholas J. Agard, Peter S. Dragovich, Ryan L. Kelly, Shion An Lim, Allison M. Beal, Ian Moench, Si-Jie Chen, Anna M. Gram, Pei‐Pei Kung · 2022 · Medicinal chemistry reviews
  45. Immunomodulatory Methods
    Cynthia Kassab, Brittany C. Parker Kerrigan, Hillary G. Caruso, Sanaalarab Al-Enazy, Amy B. Heimberger · 2019 · Elsevier eBooks
  46. Recent Advances in Approved, Withdrawn, Experimental and Investigational Drugs in Clinical Trials for Alzheimer’s disease
    Rajlaxmi Deshpande · 2022 · Medicinal & Analytical Chemistry International
  47. Morphological profiling by Cell Painting in human neural progenitor cells classifies hit compounds in a pilot drug screen for Alzheimer’s disease
    Amina McDiarmid, Katerina Gospodinova, Richard J. R. Elliott, John C. Dawson, Rebecca E. Hughes, Susan Maguire Anderson, Sophie Glen, Simon Glerup, Neil O. Carragher, Kathryn Louise Evans · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  48. N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis
    Yu-Hui Qiu, Ming Liu, Jie Zhan, Lingling Liu, Jiayi Zheng, Dan Wu, Guangliang Wu, Yefeng Cai, Shijie Zhang · 2023 · medRxiv
  49. A new era in Alzheimer’s disease management: exploring aducanumab’s potential
    Boyu Jiang · 2024 · International Conference on Biological Engineering and Medical Science (ICBioMed)
  50. Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
    Ashutosh Ranjan, Shashikesh Shukla, Shamsher Singh · 2024 · Current Drug Therapy
  51. Recent updates on immunotherapy in neurodegenerative diseases
    Jotiram Salunkhe, Rajesh Ramesh Ugale · 2024 · Brain Research
  52. Aducanumab: advancing Alzheimer’s treatment through regulation of excessive β-amyloid accumulation
    Clotilde Nsimire Katana Kachungunu, Subhash Namdeo Mashal, Priyadarshi Soumyaranjan Sahu · 2025 · Academia Immunity and Disease
  53. Safety, Tolerability, and Pharmacokinetics of Single Doses of ABBV ‐916, an Anti‐Amyloid Antibody, in Healthy Participants
    Sagar S. Bachhav, Hana Florian, Joey C Boiser, Yamin Wang, Dee‐Dee Shiller, Ulrike Graab, Shau Yu Lynch, Ole X. Graff, Hao Xiong · 2026 · Clinical and Translational Science
  54. Network meta-analysis of the efficacy of nine drugs for cognitive function in patients with Alzheimer's disease
    Shan-Shan Huang, Yun-Yun Guo · 2026 · Journal of Alzheimer's disease reports
  55. Carbon monoxide and anti-amyloid-β combination therapy modulates miR-381 and molecular biomarkers in an aluminum chloride–induced rat model of Alzheimer's disease
    Sami Awda Algaidi · 2026 · Journal of Neuroimmunology
  56. Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions
    Sampat Singh Bhati, Sampat Singh Tanwar · 2026 · Discover Neuroscience
  57. Phase 1 Trials in Alzheimer’s Disease Drug Development
    Manfred Windisch · 2022 · Cambridge University Press eBooks
  58. ADUCANUMAB NO TRATAMENTO DA DOENÇA DE ALZHEIMER
    Alexandre Teixeira do Amaral, Felipe Tochihide Iamaguti, I Ferreira, Jorge Almeida, Júlia ́Peruzzi Iamaguti, Miguel Neri Beraldo da Silva, Pedro Nakano Pereira, Éric Àzara de Oliveira, Carollayne Mendonça Rocha, Ana Flávia Fonseca de Oliveira · 2023 · RECIMA21 - Revista Científica Multidisciplinar
  59. The future of dementia prevention and treatment strategies
    里 直行 · 2020 · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics
  60. Aducanumab and lecanemab – two novel antibodies against pathologic species of amyloid beta in the treatment of Alzheimer’s disease
    Jakub Wojcieszak · 2023 · Farmacja Polska
  61. Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
    Steve Pedrini, Mike Morici, Ralph Nigel Martins · 2019 · Wiley eBooks
  62. Advances in Early Prevention of Alzheimer’s Disease in the Aged
    Liu Zhang, Yanlin Heng, Gaijing Wang · 2019 · Yangtze Medicine
  63. 2型糖尿病の心身医療( 内分泌・代謝疾患の心身医療)
    剛弘 野崎, 信行 須藤 · 2013 · 心身医学
  64. Drug information of Aducanumab and its effectiveness for Alzheimer’s disease: A clinical review
    Neel Sureshbhai Raval, Sachi Anilkumar Chavda, Dhwanil Nileshkumar Mithaiwala, S P Srinivas Nayak, Mohit Buddhdev, G. S. Chakraborthy · 2021 · International Journal of Biological and Pharmaceutical Sciences Archive
  65. ADUCANUMAB E A PROMESSA PARA O FUTURO DO TRATAMENTO DO ALZHEIMER: UMA REVISÃO SISTEMÁTICA
    Vitória Souza Saturnino, Daysianne Pereira de Lira Uchôa, Apolônio Peixoto de Queiroz · 2022 · Revista Contemporânea
  66. Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
    Sergey V. Vorobev, А. Yu. Emelin, S. N. Yanishevskij, Elena V. Kostina, Anna A. Galaeva · 2022 · Neurology Bulletin
  67. Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
    Yuu Ohno, Riley Murphy, Matthew Choi, Weijun Ou, Rachita K. Sumbria · 2022 · Journal of Visualized Experiments
  68. Neuropharmacology in Alzheimer and Huntington Disease
    Bandna Gupta, Kopal Rohatgi · 2022 · BENTHAM SCIENCE PUBLISHERS eBooks
  69. Anti-amyloid Monoclonal Antibodies in Alzheimer’s Disease: A New Hope
    Aygun N. Nasibova, Rovshan I. Khalilov, Aziz Eftekhari · 2023 · International Journal of Aging
  70. Alzheimer's disease - a review of medicinal substances and their derivatives
    Marika Więcek, Dorota Gabriela Piotrowska, Michal Krzysztof Kołodziejczyk, Iwona E. Głowacka · 2024 · Farmacja Polska
  71. Research Progress of Chemical Synthesis Drugs and Biotechnology Drugs for Alzheimer’s Disease
    学权 陈 · 2024 · Open Journal of Natural Science
  72. Genomics of Alzheimer’s disease
    Roger N. Rosenberg, Doris Lambracht‐Washington, Gang Yu, Weiming Xia · 2024 · Elsevier eBooks
  73. New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
    Mehran Joodaki, Mona Merati Shirazi, Nasrin Hosseini · 2024 · Physiology and Pharmacology
  74. The discovery of new acetylcholinesterase inhibitors as potential therapeutics for Alzheimer’s disease
    Yiyang Gao · 2021 · Journal of High School Science
  75. Additional file 1 of Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer’s disease in adults without dementia: a systematic review and meta-analysis protocol
    Takashi Nihashi, Sakurai, Keita, Takashi Kato, Kimura, Yasuyuki, Kengo Ito, Akinori Nakamura, Teruhiko Terasawa · 2024 · Figshare
  76. Monoclonal antibodies for treatment Alzheimer`s disease
    O. Gordiichuk, M. Bulekhovets, S. Bezhuk, N. Omelianchyk, D. Popshe · 2025 · Reports of Vinnytsia National Medical University
  77. Contribution à l’étude des anticorps dirigés contre le peptide Aβ et de leur implication dans l’angiopathie amyloïde cérébrale
    Yannick Chantran · 2020 · theses.fr (ABES)
  78. D-sérine : un maillon central de la physiopathologie amyloïde ?
    Eva Ploux · 2022 · theses.fr (ABES)
  79. A prospective real‐world study of the efficacy and safety of aducanumab in China: Focus on early‐onset and autosomal dominant Alzheimer's disease
    Jinwen Xiao, Binyin Li, Biao Li, Jintao Wang, Ran Tang, Chao Gao, Xiangqian Che, X. Hermione Xu, Shengdi Chen, Rujing Ren et al. · 2026 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
  80. Spontaneous and Iatrogenic Amyloid-Related Imaging Abnormalities (ARIA): Clues for Immunotherapy in Alzheimer’s Disease
    Marialuisa Zedde, Giampaolo Basso, Fabrizio Piazza, Rosario Pascarella · 2026 · Springer eBooks
  81. Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brain
    Kathryn A. Haynes, Ravi S. Pandey, Emma H. Doud, Zackary A. Cope, Gabriela J. Little, Sean-Paul Williams, Umesh Nepali, Sara K. Quinney, Ankit Nagar, Nitin Charbe et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Multifunctional tau-targeted theranostic agent for early diagnosis and autophagy-mediated therapy in Alzheimer’s disease
    Hailong Zhang, Ashok Iyaswamy, Senthilkumar Krishnamoorthi, Kejia Lu, Jia Kong, Yinchi Chen, Ravindran Jaganathan, Min Li, Man Shing Wong · 2026 · Sensors and Actuators B Chemical
  83. Aβ-targeted NIRI/dual-mode T1- and T2-weighted MRI multimodal theranostic nanoprobe for early diagnosis of Alzheimer's disease
    Hailong Zhang, Chengke Wang, Nicolas Desbois, Claude P. Gros, Man Shing Wong · 2026 · Chemical Engineering Journal
  84. Evaluating the safety of investigational anti-Alzheimer’s drugs: a comprehensive meta-analysis in the past to current decade
    Neelufar Shama Shaik, Harika Balya, S Ramamurthy, Balaji Pandiyan, E. Joel Mart, Suvarna Lakshmi Gunturu · 2026 · Dementia & Neuropsychologia
  85. Comparative effectiveness of multiple interventions for Alzheimer’s disease on ABC syndromes and QoL: A Bayesian network meta-analysis
    Fujia Gao, Guangxin Luo, Bokuan Liu, Xu Qiu, Jing Bai, Ruimin Wang · 2026 · iScience
  86. Molecular and genetic basis of alzheimer’s disease and emerging treatment Modalities
    Himanshi Varshney, Yasir Hasan Siddique · 2026 · Neurodegenerative Disease Management
  87. Passive immunotherapy in Alzheimer’s disease: biomarkers, biological staging, and emerging therapeutic strategies
    Almas Surhan, Joti Oad, Beesham Kumar, Shafaq Noor Memon, Chandani Essrani, Faqeer Muhammad, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Taha Basit Ameen, Ahsan Sauleh et al. · 2026 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
  88. Engineering human brain microphysiological systems for alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) modeling and drug testing: translational promise, limitations, and future directions
    Yeoheung Yun, Satarupa Jena, Hailey Egido-Betancourt, Samuel Uzoechi, Doo Yeon Kim, Jin-Moo Lee, Juliane Nguyen · 2026 · Advanced Drug Delivery Reviews